Takeda Pharmaceutical (NYSE:TAK) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Takeda Pharmaceutical (NYSE:TAK) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other brokerages have also recently issued reports on TAK. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, November 3rd. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded up $0.31 during midday trading on Friday, hitting $21.43. 3,751,438 shares of the stock traded hands, compared to its average volume of 2,958,236. The firm has a 50-day moving average of $19.40 and a two-hundred day moving average of $17.78. The firm has a market capitalization of $68.68 billion, a P/E ratio of 28.20 and a beta of -0.02. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15. Takeda Pharmaceutical has a one year low of $13.91 and a one year high of $21.73.

Insider Buying and Selling at Takeda Pharmaceutical

In related news, insider Andrew Plump sold 116,191 shares of Takeda Pharmaceutical stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the transaction, the insider directly owned 145,465 shares in the company, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Giles Platford sold 55,617 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $20.90, for a total value of $1,162,395.30. Following the completion of the sale, the insider owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. The trade was a 17.07% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 238,974 shares of company stock worth $4,549,461. 0.04% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TAK. Renaissance Technologies LLC raised its stake in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares during the period. Quantinno Capital Management LP boosted its position in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares during the period. Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after purchasing an additional 60,725 shares during the period. Bleakley Financial Group LLC boosted its position in shares of Takeda Pharmaceutical by 2.8% in the third quarter. Bleakley Financial Group LLC now owns 444,988 shares of the company’s stock worth $8,094,000 after purchasing an additional 12,032 shares during the period. Finally, Ethic Inc. increased its stake in shares of Takeda Pharmaceutical by 19.5% in the third quarter. Ethic Inc. now owns 436,514 shares of the company’s stock worth $7,940,000 after purchasing an additional 71,261 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.